CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 177 filers reported holding CRINETICS PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is 0.81 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,338,003 | +10.1% | 44,990 | -32.3% | 0.00% | +100.0% |
| Q4 2022 | $1,215,632 | -37.5% | 66,428 | -32.9% | 0.00% | -50.0% |
| Q3 2022 | $1,946,000 | -5.4% | 99,068 | -10.2% | 0.00% | 0.0% |
| Q2 2022 | $2,057,000 | -15.0% | 110,278 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $2,421,000 | -25.8% | 110,278 | -3.9% | 0.00% | -33.3% |
| Q4 2021 | $3,261,000 | -20.7% | 114,768 | -41.3% | 0.00% | -25.0% |
| Q3 2021 | $4,114,000 | +174.1% | 195,438 | +145.5% | 0.00% | +300.0% |
| Q2 2021 | $1,501,000 | +18.1% | 79,618 | -4.3% | 0.00% | 0.0% |
| Q1 2021 | $1,271,000 | +71.8% | 83,158 | +58.6% | 0.00% | 0.0% |
| Q4 2020 | $740,000 | -23.4% | 52,438 | -15.0% | 0.00% | 0.0% |
| Q3 2020 | $966,000 | -13.5% | 61,678 | -3.3% | 0.00% | -50.0% |
| Q2 2020 | $1,117,000 | -79.4% | 63,758 | -82.7% | 0.00% | -60.0% |
| Q1 2020 | $5,430,000 | +10.8% | 369,448 | +89.2% | 0.01% | -16.7% |
| Q4 2019 | $4,899,000 | +52.0% | 195,238 | -8.9% | 0.01% | +50.0% |
| Q3 2019 | $3,224,000 | +85.1% | 214,368 | +207.7% | 0.00% | 0.0% |
| Q2 2019 | $1,742,000 | +43.4% | 69,670 | +30.5% | 0.00% | +33.3% |
| Q1 2019 | $1,215,000 | -24.9% | 53,370 | -1.1% | 0.00% | -25.0% |
| Q4 2018 | $1,618,000 | -40.4% | 53,960 | -43.1% | 0.00% | -33.3% |
| Q3 2018 | $2,716,000 | – | 94,810 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,126,579 | $33,504,459 | 14.02% |
| New Leaf Venture Partners, L.L.C. | 141,000 | $4,193,340 | 5.38% |
| First Light Asset Management, LLC | 1,583,329 | $47,088,204 | 4.47% |
| Paradigm Biocapital Advisors LP | 2,178,737 | $64,795,638 | 4.40% |
| Bain Capital Life Sciences Investors, LLC | 1,275,552 | $37,934,916 | 4.24% |
| Altium Capital Management LP | 262,000 | $7,791,880 | 4.06% |
| 5AM Venture Management, LLC | 462,286 | $13,748,386 | 3.96% |
| MPM BioImpact LLC | 479,053 | $14,247,036 | 3.80% |
| Affinity Asset Advisors, LLC | 450,000 | $13,383,000 | 3.76% |
| Opaleye Management Inc. | 370,000 | $11,003,800 | 3.58% |